PharmD Info

A forum for Indian Pharmacy Professionals

The Latest Indian Pharma News, Pharmacist Day Celebrations, Pharmacy Council of India Notifications, Seminars and Conferences Alerts. Marketing News
Forum rules: Forum rules: Dear User, Kindly read our forum rules before you proceed with our PharmD Info, Your first 5 posts/topics requires moderator approval and this website is purely meant for educational and knowledge sharing purpose only so you should not make any topics/replies/messages which criticize, threaten or abuse any member, pharmacy governing bodies and organizations. Your post will be deleted automatically by our BB Pruning System if your topic is not viewed by members for more than 5 days. So, make sure that your topics and its related contents are unique and valuable. We expect you to be an active member of our forum to continue with your free membership.Kindly note that if a member received more than five warnings from moderator/members they will be blocked automatically by our Bulletin Board system.
  • User avatar
Sotagliflozin has the potential to become the first oral medication to be approved for the treatment of type 1 diabetes, and the first new innovative treatment for the condition since insulin was discovered more than a century ago.

An investigational new oral drug for type 1 diabetes has shown promise in improving glucose control when used in conjunction with insulin, compared with using insulin alone[1].

According to the authors of the study (13 September 2017) no oral medication has been approved for use in combination with insulin to lower the glucose level in patients with type 1 diabetes, so sotagliflozin has the potential to become the first new treatment innovation for the condition since insulin was discovered more than a century ago.
The double-blind, randomised control trial comprised 1,402 trial participants with type 1 diabetes who were assigned to either 400mg of sotagliflozin or placebo, to be taken daily alongside their insulin therapy.

At week 24, the results showed that a significantly larger proportion of patients taking the active drug, which works by inhibiting two sodium-glucose transporters, achieved the primary end point of a glycated haemoglobin level lower than 7% and no episodes of severe hypoglycaemia or diabetic ketoacidosis.

The use of sotagliflozin was also associated with significant decreases in fasting plasma glucose level, insulin dose, weight and systolic blood pressure.

However, the research also found that rates of diabetic ketoacidosis and hypoglycaemia were higher among patients who received sotagliflozin but did not achieve the target glycated haemoglobin level than in the placebo group.

“Sotagliflozin added to insulin therapy can potentially help patients with type 1 diabetes improve their glucose control and hopefully manage the disease with fewer complications,” said Satish Garg, professor of medicine and paediatrics for the Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus and lead author of the study.

“This would not be a replacement for insulin; it is an adjunctive therapy. However, because it works in the gut and the kidneys, it doesn’t require insulin to have an effect.”

The researchers said that the trial had some limitations however, primarily because the long-term effects of sotagliflozin cannot be determined in 24 weeks.

ICH just released E19 Guideline. This new guidelin[…]

Dear Colleagues, Greetings from ISoP South Asian […]

This condition is caused by high levels of insulin[…]

Enrollment is OPEN for the Fall cohort of the Foun[…]

PharmD Info - Highlights